Literature DB >> 16937435

Efficacy of ultrasonography and alpha-fetoprotein on early detection of hepatocellular carcinoma.

Fen-Yu Ren1, Xi-Xu Piao, Ai-Lian Jin.   

Abstract

AIM: To evaluate the effectiveness of ultrasonographic screening for early detection of hepatocellular carcinoma (HCC).
METHODS: The data of 14968 patients who had ultrasonography (US) for chronic liver diseases were collected into a database program from June 1995 to June 2005. The risk factors for HCC were also studied. A total of 6089 patients who had repeated US were enrolled, 264 patients were diagnosed with HCC during follow-up (mean, 39 mo).
RESULTS: The detection rate of small HCC (<= 3 cm in diameter) was 67.7%. The tumor size detected by screening at the intervals of 6 mo was significantly smaller than that at longer intervals. Only 29.3% of HCC patients had an elevated serum alpha fetoprotein (AFP) level above 400 ng/mL. The risk of HCC development during follow-up was higher in patients with liver cirrhosis (10.9%) and hepatitis C (9.0%) than in patients with chronic hepatitis (4.2%), hepatitis B (4.9%) and non-B, non-C hepatitis (NBNC, 3.9%).
CONCLUSION: US screening at a interval of 6 mo is beneficial to high-risk patients over 40 years old and the early detection of HCC prolongs survival.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16937435      PMCID: PMC4087829          DOI: 10.3748/wjg.v12.i29.4656

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  33 in total

Review 1.  Prognostic prediction and treatment strategy in hepatocellular carcinoma.

Authors:  Jordi Bruix; Josep M Llovet
Journal:  Hepatology       Date:  2002-03       Impact factor: 17.425

2.  Prospective study of early detection for primary liver cancer.

Authors:  B Yang; B Zhang; Y Xu; W Wang; Y Shen; A Zhang; Z Xu
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

3.  Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America.

Authors:  M J Tong; L M Blatt; V W Kao
Journal:  J Gastroenterol Hepatol       Date:  2001-05       Impact factor: 4.029

4.  Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications.

Authors:  J C Sheu; J L Sung; D S Chen; P M Yang; M Y Lai; C S Lee; H C Hsu; C N Chuang; P C Yang; T H Wang
Journal:  Gastroenterology       Date:  1985-08       Impact factor: 22.682

Review 5.  Environmental factors and risk for hepatocellular carcinoma.

Authors:  Mimi C Yu; Jian-Min Yuan
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

6.  Risk factors for hepatocellular carcinoma among patients with chronic liver disease.

Authors:  H Tsukuma; T Hiyama; S Tanaka; M Nakao; T Yabuuchi; T Kitamura; K Nakanishi; I Fujimoto; A Inoue; H Yamazaki
Journal:  N Engl J Med       Date:  1993-06-24       Impact factor: 91.245

7.  A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis.

Authors:  K Ikeda; S Saitoh; I Koida; Y Arase; A Tsubota; K Chayama; H Kumada; M Kawanishi
Journal:  Hepatology       Date:  1993-07       Impact factor: 17.425

8.  Hepatocellular carcinoma in Italian patients with cirrhosis.

Authors:  M Colombo; R de Franchis; E Del Ninno; A Sangiovanni; C De Fazio; M Tommasini; M F Donato; A Piva; V Di Carlo; N Dioguardi
Journal:  N Engl J Med       Date:  1991-09-05       Impact factor: 91.245

9.  A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal.

Authors:  J P Villeneuve; M Desrochers; C Infante-Rivard; B Willems; G Raymond; M Bourcier; J Côté; G Richer
Journal:  Gastroenterology       Date:  1994-04       Impact factor: 22.682

10.  Identification and screening of 416 patients with chronic hepatitis at high risk to develop hepatocellular cancer.

Authors:  S A Curley; F Izzo; A Gallipoli; M de Bellis; F Cremona; V Parisi
Journal:  Ann Surg       Date:  1995-09       Impact factor: 12.969

View more
  6 in total

1.  Cirrhosis and Chronic Viral Hepatitis as Risk Factors for Hepatocellular Carcinoma: Romanian Single-clinic Experience.

Authors:  Cristin Vere Constantin; Costin Teodor Streba; Ion Rogoveanu; Liliana Nita-Stefanescu; Alin Gabriel Ionescu
Journal:  Maedica (Buchar)       Date:  2010-12

2.  Treatment of liver hydatidosis: how to treat an asymptomatic carrier?

Authors:  Bernardo Frider; Edmundo Larrieu
Journal:  World J Gastroenterol       Date:  2010-09-07       Impact factor: 5.742

3.  Prospective screening increases the detection of potentially curable hepatocellular carcinoma: results in 8,900 high-risk patients.

Authors:  Francesco Izzo; Mauro Piccirillo; Vittorio Albino; Raffaele Palaia; Andrea Belli; Vincenza Granata; Sergio Setola; Roberta Fusco; Antonella Petrillo; Raffaele Orlando; Grazia Tosone; Fabrizio Scordino; Steven A Curley
Journal:  HPB (Oxford)       Date:  2013-04-22       Impact factor: 3.647

4.  Comparison of a multitarget blood test to ultrasound and alpha-fetoprotein for hepatocellular carcinoma surveillance: Results of a network meta-analysis.

Authors:  Amit G Singal; Benjamin Haaland; Neehar D Parikh; A Burak Ozbay; Carol Kirshner; Shubham Chakankar; Kyle Porter; Jagpreet Chhatwal; Turgay Ayer
Journal:  Hepatol Commun       Date:  2022-08-09

5.  Chronic viral hepatitis and hepatocellular carcinoma.

Authors:  Yagil Barazani; Jonathan R Hiatt; Myron J Tong; Ronald W Busuttil
Journal:  World J Surg       Date:  2007-06       Impact factor: 3.282

6.  Hepatocellular carcinoma screening and surveillance in 2293 chronic hepatitis B patients in an endemic area.

Authors:  Teerapat Ungtrakul; Chulabhorn Mahidol; Pattra Chun-On; Charlie Laohapand; Surachate Siripongsakun; Akeanong Worakitsitisatorn; Sirachat Vidhayakorn; Wariya Boonchuay; Jiraporn Dechma; Gaidganok Sornsamdang; Kamonwan Soonklang; Tassanee Sriprayoon; Tawesak Tanwandee; Chirayu U Auewarakul
Journal:  World J Gastroenterol       Date:  2016-09-14       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.